Myelodysplastic Syndrome Clinical Trial

Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS

Summary

This research study is evaluating how to best tailor blood transfusion decisions to match the quality of life changes experienced by individual patients with MDS.

View Full Description

Full Description

Each patient with MDS reacts differently to blood transfusions; some will feel better after transfusion, while others may not. The main purpose of this survey study is to determine whether it is possible to use quality of life changes - as measured by a validated questionnaire - experienced by individual patients to help physicians and patients with MDS make decisions regarding future blood transfusions. This research is being done because the investigators hope to help doctors better understand the impact of blood transfusions on the quality of life of each patient.

The study uses a standardized MDS-specific quality of life questionnaire that participants will fill out before and after an upcoming transfusion. The investigators will compare the scores of these questionnaires and notify both the participant and provider if the participant has experienced any changes (positive or negative) in his/her quality of life before and after transfusion. The investigators' hope is that doctor-patient teams will use this quality of life information to determine whether the participant should continue receiving transfusions, decrease the frequency of transfusions, or stop receiving transfusions altogether if not needed.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age > 18 years of age
Patients with MDS
Patients approaching an Hb of 8.5 g/dL during enrollment period OR
Patients with >1 transfusion scheduled during an 8-week period
Ability to read and understand English

Exclusion Criteria:

Age <18 years
Cr > 2
Known CHF
Unstable Angina
Hb level below 7.5 g/dL or above 8.5 g/dL
No plan for future transfusion.
Patient enrollment will happen after patient has consented and scheduled their first/next transfusion.
Patient will not be enrolled if no future transfusions are scheduled.

Study is for people with:

Myelodysplastic Syndrome

Estimated Enrollment:

62

Study ID:

NCT03660228

Recruitment Status:

Completed

Sponsor:

Dana-Farber Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Estimated Enrollment:

62

Study ID:

NCT03660228

Recruitment Status:

Completed

Sponsor:


Dana-Farber Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider